Stability of Enzyme Conjugates in ELISA, CLIA and LFA

Define exactly what is being stored

Start with a description of the product that will actually be used: conjugate identity, concentration, formulation, fill volume, container and intended handling. A concentrated stock in a sealed vial is not equivalent to a dilute working reagent, an open instrument reservoir or a conjugate dried into a porous pad.

Also identify the binding partner. An enzyme linked to an antibody must retain the relevant antigen recognition. An enzyme-streptavidin reagent has a different affinity function. Both require functional evidence, but the binding measurements cannot simply be exchanged.

Do not let a platform name substitute for this description. A CLIA may use liquid or dried reagents, and an ELISA can be implemented in a paper device. The relevant distinction is what the conjugate experiences between manufacture and measurement.

Separate catalytic activity, binding and delivery

A useful stability panel asks more than one question. Catalytic testing establishes whether the enzyme can still convert a selected substrate under defined conditions. A binding experiment tests the recognition function. A complete-assay experiment determines whether those functions still combine successfully in the final workflow.

Cheng and colleagues examined enzyme and binding activity in an alkaline phosphatase (ALP)-streptavidin conjugate over storage. This affinity-reagent example highlights the need to distinguish the two functions. It does not establish a storage condition for every enzyme-antibody conjugate.

Use a reporter assay that can detect the change of interest

Measure activity within a response range where a decline would be visible. An endpoint driven to saturation can conceal a meaningful difference between stored and reference material. Keep substrate preparation, reaction temperature, timing and instrument settings controlled, and report the method alongside the result.

Where useful, compare equal volumes of the final reagent as well as a normalized enzyme amount. The first addresses performance as supplied; the second can help investigate the retained material. Normalization must not hide concentration changes, loss during handling or poor recovery from the device.

Test the conjugate in the binding task it must perform

Include a target-dependent measurement with a suitable reference and a background control. A separate affinity measurement can help explain an unexpected result, but the decisive application check uses the conjugate in the relevant assay sequence. Free enzyme activity is not evidence that the attached antibody still binds appropriately.

For a dried LFA, add delivery measurements. A conjugate may perform adequately after deliberate extraction yet release poorly during normal capillary flow. Compare extraction-based recovery with the response obtained when the strip is operated as intended. Use the conjugation guide when the starting material already shows inconsistent binding or catalysis before storage.

Develop formulation and packaging together

Formulation screening should begin with the identified failure mode and final use conditions. Candidate excipients, buffer systems and protein concentrations need both a storage assessment and a compatibility check in the assay. A formulation that preserves activity in a vial can still change washing, background, reconstitution or capillary delivery.

Liquid stability needs the final concentration and handling history

Test the concentration intended for storage and the dilution used in operation. Include the container-contact and access conditions relevant to the product. If freezing, thawing or transport excursions are expected, define them as separate exposures rather than assuming that the unopened-storage study covers them.

Monitor changes that can alter the effective reagent dose, such as incomplete mixing, visible particulates or poor recovery. These observations help direct further characterization; appearance alone cannot establish activity, purity or binding function. Keep the analytical readouts linked to the actual performance problem.

Drying introduces both process loss and storage loss

Compare the liquid starting material with freshly dried and reconstituted material before evaluating aged samples. This separates a loss caused by drying from deterioration during storage. A low initial recovery followed by little further change should not be described as preservation of the original performance.

Ford and Dawson showed that carbohydrate choice influenced retained activity in freeze-dried alkaline phosphatase. Their study supports screening excipients in a defined system; it does not make one sugar a universal solution or establish retention of an attached antibody's function.

In a separate ALP study, the same investigators examined container type, temperature and humidity. That evidence makes packaging part of the stability question. Evaluate the intended vial closure or sealed pouch together with the dried reagent, including relevant moisture protection and the period after opening.

Ramachandran and colleagues demonstrated dry preservation of an HRP-antibody reagent and its substrate before incorporating them into a paper device. The transferable lesson is the staged evaluation of components and then the assembled assay. The reported outcome belongs to that formulation and device, not to HRP conjugates as a class.

Design the study around the proposed claim

Write the stability question before selecting temperatures or time points. Shelf life in an unopened package, tolerance of shipping conditions and usable time after opening are different claims. Each needs an exposure sequence that represents the proposed use and an endpoint capable of detecting unacceptable change.

The public scope of ISO 23640 includes real-time and accelerated evaluation, transport, in-use stability and changes that may affect stability. Use the applicable current requirements when preparing a formal study. The framework here is a development guide, not a substitute for the full standard or product-specific obligations.

Use stress studies to learn, and real-time studies to support storage conclusions

Stress conditions can reveal vulnerable components and help rank candidate formulations. They do not automatically reproduce the mechanism operating under intended storage. Avoid converting a short high-temperature result into a shelf-life claim with an assumed universal multiplier.

Maintain a real-time study in the intended configuration. If an accelerated model is used, document the model, its supporting observations and where extrapolation is uncertain. Revisit the interpretation when failure patterns differ across conditions rather than forcing all results onto one trend.

Build references and sample coverage into the design

Use a reference whose own stability is justified. Otherwise, stored material and reference may decline together and appear unchanged in a relative comparison. Control the other assay components, or assess them independently when the purpose is to evaluate the whole kit.

Include blanks, samples near the relevant decision region and material spanning the working range. Evaluate variability as well as average response. A high-level positive alone is a poor sentinel for deterioration that first affects low-level separation or background.

Choose independent lots and replicates according to the claim and sources of variability. Record actual exposure histories, deviations and assay conditions. Define acceptance criteria before examining the aged-sample results, including what constitutes unacceptable change in complete-assay performance.

Use disagreement between endpoints to guide the investigation

If catalytic activity falls and the complete assay also declines, investigate reporter preservation while checking that the activity method remains controlled. If catalysis is retained but target-dependent response decreases, examine binding, effective conjugate dose and delivery. Neither pattern proves a single cause without discriminating controls.

If background rises while the positive signal remains strong, do not classify the reagent as stable solely on positive recovery. Investigate changes in nonspecific retention or physical state. The blocking and interference guide provides relevant controls for that branch of the investigation.

For a strip with delayed migration or poor release, examine the dried reagent and device as a combined system. For a light-emitting assay with altered signal timing, distinguish conjugate change from substrate or acquisition change using the chemiluminescent substrate guide.

The final report should name the material, packaging, exposures, methods, acceptance criteria and tested interval. State which conclusions are demonstrated and which remain provisional. Extend a stability claim only when the evidence covers the proposed conditions, and return to the immunoassay signal guide collection for related development decisions.